Next Generation Drug Conjugates Market by Product (Enhertu, Amvuttra), Type (Antibody-Small Molecule), Target Ligand (Antibody, Peptide), Payload Type (Oligonucleotide, Radionuclide), Indication (Breast Cancer, Prostate Cancer) - Global Forecast to 2035
The global next generation drug conjugates market is estimated to reach USD 42.55 billion by 2035 from USD 15.75 billion in 2026, at a CAGR of 11.7% during the forecast period of 2026 to 2035. The global next generation drug conjugates market is projected to witness strong growth over the forecast period, supported by rising adoption of targeted therapies, continued innovation in linker, payload, and targeting ligand technologies, and increasing investment in oncology-focused drug development. Market estimates from published industry sources indicate robust double-digit growth through 2034, reflecting strong clinical and commercial momentum for these therapies. However, safety concerns, manufacturing complexity, and high treatment costs are expected to remain key factors restraining broader market expansion.
“The Enhertu product segment accounted for the largest share by product in the next generation drug conjugates market in 2025.”
Based on product, the next generation drug conjugates market is broadly segmented into Enhertu (fam-trastuzumab deruxtecan-nxki), Pluvicto (lutetium Lu 177 vipivotide tetraxetan), Amvuttra (vutrisiran), Trodelvy (sacituzumab govitecan-hziy), Sacituzumab tirumotecan, Patritumab Deruxtecan (HER3-DXd), 225Ac-PSMA-617, other commercialized products and other pipeline products. The ENHERTU segment held the largest market share in 2025. This leadership can be attributed to several factors, including its strong efficacy across multiple HER2-expressing tumor types, rapid label expansion beyond metastatic breast cancer into broader solid tumor settings, and its differentiated DXd payload and bystander effect, which have strengthened physician confidence and treatment adoption. In addition, Enhertu has benefited from growing global commercial penetration, increasing use in earlier lines of therapy, and strong backing from AstraZeneca and Daiichi Sankyo’s extensive development and commercialization capabilities.
“The antibody-small molecule drug conjugate segment accounted for the largest share by type segment in the next generation drug conjugates market in 2025.”
Based on end users, the global next generation drug conjugates market is segmented into antibody-small molecule drug conjugates, ligand-oligonucleotide conjugates, small molecule-radionuclide conjugates, peptide-radionuclide conjugates, and other conjugate types. In 2025, the antibody-small molecule segment accounted for the largest share of the market. This is primarily because antibody-drug conjugates are the most clinically established and commercially advanced class within targeted conjugates, with continued technological progress improving outcomes across multiple tumor types.
“North America is growing at the highest CAGR in the next generation drug conjugates market from 2026 to 2035.”
The next generation drug conjugates market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. During the forecast period, the North American region is estimated to grow at the highest CAGR. This growth is expected to be supported by the region’s strong concentration of biopharmaceutical innovation, early adoption of advanced targeted therapies and the presence of key market participants, such as Novartis, Pfizer and Alnylam, actively developing and commercializing next generation drug conjugates.
The primary interviews conducted for this report can be categorized as follows:
This research report categorizes the next generation drug conjugates market by product (Enhertu [fam-trastuzumab deruxtecan-nxki], Pluvicto [lutetium Lu 177 vipivotide tetraxetan], AMVUTTRA [vutrisiran], TRODELVY [sacituzumab govitecan-hziy], Sacituzumab tirumotecan, Patritumab Deruxtecan [HER3-DXd], 225Ac-PSMA-617, other commercialized products and other pipeline products); by type: antibody-small molecule drug conjugate, ligand-oligonucleotide conjugate, small molecule-radionuclide conjugate, peptide-radionuclide conjugate, and other conjugate types; by targeting ligand: antibody, amino sugar, small molecule and peptide; by payload type: small molecule, oligonucleotide, and radionuclide; by indications: breast cancer, prostate cancer, hATTR with polyneuropathy, primary hyperlipidemia and other indications; and by region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the next generation drug conjugates market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the next generation drug conjugates market. Competitive analysis of top players and upcoming startups in the next generation drug conjugates market ecosystem is covered in this report.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall next generation drug conjugates market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
“The Enhertu product segment accounted for the largest share by product in the next generation drug conjugates market in 2025.”
Based on product, the next generation drug conjugates market is broadly segmented into Enhertu (fam-trastuzumab deruxtecan-nxki), Pluvicto (lutetium Lu 177 vipivotide tetraxetan), Amvuttra (vutrisiran), Trodelvy (sacituzumab govitecan-hziy), Sacituzumab tirumotecan, Patritumab Deruxtecan (HER3-DXd), 225Ac-PSMA-617, other commercialized products and other pipeline products. The ENHERTU segment held the largest market share in 2025. This leadership can be attributed to several factors, including its strong efficacy across multiple HER2-expressing tumor types, rapid label expansion beyond metastatic breast cancer into broader solid tumor settings, and its differentiated DXd payload and bystander effect, which have strengthened physician confidence and treatment adoption. In addition, Enhertu has benefited from growing global commercial penetration, increasing use in earlier lines of therapy, and strong backing from AstraZeneca and Daiichi Sankyo’s extensive development and commercialization capabilities.
“The antibody-small molecule drug conjugate segment accounted for the largest share by type segment in the next generation drug conjugates market in 2025.”
Based on end users, the global next generation drug conjugates market is segmented into antibody-small molecule drug conjugates, ligand-oligonucleotide conjugates, small molecule-radionuclide conjugates, peptide-radionuclide conjugates, and other conjugate types. In 2025, the antibody-small molecule segment accounted for the largest share of the market. This is primarily because antibody-drug conjugates are the most clinically established and commercially advanced class within targeted conjugates, with continued technological progress improving outcomes across multiple tumor types.
“North America is growing at the highest CAGR in the next generation drug conjugates market from 2026 to 2035.”
The next generation drug conjugates market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. During the forecast period, the North American region is estimated to grow at the highest CAGR. This growth is expected to be supported by the region’s strong concentration of biopharmaceutical innovation, early adoption of advanced targeted therapies and the presence of key market participants, such as Novartis, Pfizer and Alnylam, actively developing and commercializing next generation drug conjugates.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side - 70% and Demand Side - 30%
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
- By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East - 5%
- Alnylam Pharmaceuticals
- Gilead Sciences, Inc.
- Novartis AG
- AstraZeneca
- Daiichi Sankyo Company, Limited
- Ionis Pharmaceuticals, Inc.
- Rakuten Group
- Novo Nordisk
- ADC Therapeutics SA
- Sanofi
- Arrowhead Pharmaceuticals
- Abbvie
- Regeneron Pharmaceuticals, Inc.
- Bicycle therapeutics
- Avidity Biosciences
- Silence Therapeutics
- MediLink Therapeutics
- SystImmune, Inc.
- Actinium Pharmaceuticals
- Alphamab Oncology
- Fusion Pharma
- Orano group
- PepGen Inc
- Tubulis GmbH
- Clarity Pharmaceuticals
This research report categorizes the next generation drug conjugates market by product (Enhertu [fam-trastuzumab deruxtecan-nxki], Pluvicto [lutetium Lu 177 vipivotide tetraxetan], AMVUTTRA [vutrisiran], TRODELVY [sacituzumab govitecan-hziy], Sacituzumab tirumotecan, Patritumab Deruxtecan [HER3-DXd], 225Ac-PSMA-617, other commercialized products and other pipeline products); by type: antibody-small molecule drug conjugate, ligand-oligonucleotide conjugate, small molecule-radionuclide conjugate, peptide-radionuclide conjugate, and other conjugate types; by targeting ligand: antibody, amino sugar, small molecule and peptide; by payload type: small molecule, oligonucleotide, and radionuclide; by indications: breast cancer, prostate cancer, hATTR with polyneuropathy, primary hyperlipidemia and other indications; and by region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the next generation drug conjugates market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the next generation drug conjugates market. Competitive analysis of top players and upcoming startups in the next generation drug conjugates market ecosystem is covered in this report.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall next generation drug conjugates market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (increasing clinical success and regulatory approvals of antibody-drug conjugates, technological advancements in linker chemistry and payload development), restraints (high development and manufacturing costs associated with complex biologics), opportunities (expansion of drug conjugates into non-oncology therapeutic areas) and challenges (complex clinical trial design and patient selection requirements) are influencing the growth of next generation drug conjugates market
- Product Development/Innovation: Detailed insights on newly launched products of the next generation drug conjugates market
- Market Development: Comprehensive information about lucrative markets – the report analyses the next generation drug conjugates market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the next generation drug conjugates market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Alnylam Pharmaceuticals (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), AstraZeneca (UK), Daiichi Sankyo Company, Limited (Japan), Ionis Pharmaceuticals, Inc. (US), among others in the next generation drug conjugates market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED AND REGIONS CONSIDERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 NEXT-GENERATION DRUG CONJUGATES MARKET OVERVIEW
3.2 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND & REGION
3.3 NEXT-GENERATION DRUG CONJUGATES MARKET: GEOGRAPHIC SNAPSHOT
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Increasing clinical success and regulatory approvals of antibody-drug conjugates
4.2.1.2 Technological advancements in linker chemistry and payload development
4.2.2 RESTRAINTS
4.2.2.1 High development and manufacturing costs associated with complex biologics
4.2.3 OPPORTUNITIES
4.2.3.1 Expansion of drug conjugates into non-oncology therapeutic areas
4.2.3.2 Increasing developments of novel conjugate platforms
4.2.4 CHALLENGES
4.2.4.1 Concerns related to biocompatibility, safety, and adverse immune responses
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
4.4.2 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE
4.4.3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE
4.4.4 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE SELLING PRICE, BY KEY PLAYER, 2025 (USD)
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
5.5.3 AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD)
5.6 KEY CONFERENCES & EVENTS
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.8 INVESTMENT & FUNDING ACTIVITY
5.9 IMPACT OF US TARIFFS—NEXT-GENERATION DRUG CONJUGATES MARKET
5.9.1 INTRODUCTION
5.9.2 KEY TARIFF RATES
5.9.3 PRICE IMPACT ANALYSIS
5.9.4 IMPACT ON COUNTRIES/REGIONS
5.9.4.1 North America
5.9.4.2 Europe
5.9.4.3 Asia Pacific
5.9.5 IMPACT ON END-USE INDUSTRIES
5.9.5.1 Hospitals
5.9.5.2 Specialty clinics and cancer centers
5.9.5.3 Other specialty care settings
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY TECHNOLOGIES
6.1.1.1 New-generation payload chemistries
6.1.1.2 Radioligand/theranostic conjugate engineering
6.1.2 ADJACENT TECHNOLOGIES
6.1.2.1 Protein engineering/antibody engineering
6.1.3 COMPLEMENTARY TECHNOLOGIES
6.1.3.1 Diagnostic imaging/theranostics workflows
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 FUTURE APPLICATIONS
6.4 IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET
6.4.1 TOP USE CASES AND MARKET POTENTIAL
6.4.2 CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION DRUG CONJUGATES MARKET
6.4.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.4.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN NEXT-GENERATION DRUG CONJUGATES MARKET
6.5 PIPELINE ANALYSIS
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT
7.1.2.1 Reimbursement scenario
7.1.3 INDUSTRY STANDARDS
7.1.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM END USERS
8.5 MARKET PROFITABILITY
9 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 ENHERTU
9.2.1 BROAD CLINICAL ADOPTION AND REGULATORY EXPANSION OF TARGETED ADC THERAPIES DRIVE MARKET GROWTH
9.3 PLUVICTO
9.3.1 EXPANDING USE OF TARGETED RADIOLIGAND THERAPY IN PROSTATE CANCER TO DRIVE MARKET GROWTH
9.4 AMVUTTRA
9.4.1 ADVANCING RNAI THERAPEUTICS THROUGH DURABLE GENE SILENCING AND EXPANDED INDICATION REACH
9.5 TRODELVY
9.5.1 RISING GOVERNMENT APPROVALS FOR BREAST CANCER TREATMENTS TO DRIVE MARKET GROWTH
9.6 SACITUZUMAB TIRUMOTECAN
9.6.1 ADVANCING NEXT-GENERATION ADC PAYLOAD INNOVATION IN NDC MARKET
9.7 PATRITUMAB DERUXTECAN
9.7.1 ADVANCEMENTS IN HER3-DIRECTED ANTIBODY-DRUG CONJUGATES TO AID GROWTH
9.8 225AC-PSMA-617
9.8.1 POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO SUPPORT MARKET GROWTH
9.9 OTHER COMMERCIALIZED PRODUCTS
9.10 OTHER PIPELINE PRODUCTS
10 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE
10.1 INTRODUCTION
10.2 ANTIBODY–SMALL MOLECULE CONJUGATES
10.2.1 ENHANCED CLINICAL UTILITY AND TECHNOLOGICAL INNOVATION TO DRIVE MARKET
10.3 PEPTIDE–RADIONUCLIDE CONJUGATES
10.3.1 INNOVATIONS IN PRECISION ONCOLOGY APPLICATIONS AND TECHNOLOGICAL ADVANCEMENTS SUPPORT GROWTH
10.4 LIGAND–OLIGONUCLEOTIDE CONJUGATES
10.4.1 ENHANCED DELIVERY AND TISSUE TARGETING CAPABILITIES OF LIGAND–OLIGONUCLEOTIDE CONJUGATES DRIVE GROWTH
10.5 OTHER DRUG CONJUGATES
11 NEXT-GENERATION DRUG MARKET, BY TARGET LIGAND
11.1 INTRODUCTION
11.2 ANTIBODIES
11.2.1 ADVANCEMENTS IN ANTIBODY ENGINEERING AND EXPANDING TARGET DIVERSITY DRIVE GROWTH
11.3 AMINO SUGARS
11.3.1 GROWING ADOPTION OF GALNAC-BASED LIVER-TARGETING PLATFORMS DRIVES EXPANSION
11.4 SMALL MOLECULES
11.4.1 EXPANDING USE OF SMALL-MOLECULE TARGETING LIGANDS IS BROADENING THE NEXT-GENERATION DRUG CONJUGATES MARKET
11.5 PEPTIDES
11.5.1 EXPANDING CLINICAL PIPELINES AND TUMOR-TARGETING INNOVATIONS PROPEL GROWTH
12 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE
12.1 INTRODUCTION
12.2 SMALL-MOLECULE PAYLOADS
12.2.1 RISING ADOPTION OF HIGHLY POTENT, NEXT-GENERATION PAYLOADS AND ADVANCED LINKER TECHNOLOGIES IS ACCELERATING GROWTH
12.3 OLIGONUCLEOTIDE PAYLOADS
12.3.1 RISING ADOPTION OF RNA-BASED GENE-SILENCING THERAPIES AND LONG-ACTING CONJUGATE PLATFORMS TO DRIVE MARKET
12.4 RADIONUCLIDE PAYLOADS
12.4.1 EXPANDING RADIOLIGAND THERAPY ADOPTION AND ADVANCEMENTS IN ISOTOPE TECHNOLOGIES SUPPORT MARKET GROWTH
13 NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION
13.1 INTRODUCTION
13.2 BREAST CANCER
13.2.1 RISING INCIDENCE AND INCREASING ADOPTION OF TARGETED ADC THERAPIES TO DRIVE MARKET
13.3 HATTR WITH POLYNEUROPATHY
13.3.1 ADVANCEMENTS IN RNA-BASED GENE-SILENCING THERAPIES AND INCREASING DIAGNOSIS RATES ARE DRIVING GROWTH
13.4 PROSTATE CANCER
13.4.1 EXPANDING ADOPTION OF PSMA-TARGETED RADIOLIGAND THERAPIES IS DRIVING GROWTH
13.5 PRIMARY HYPERLIPIDEMIA
13.5.1 INCREASING ADOPTION OF LONG-ACTING RNA-BASED THERAPIES DRIVES MARKET GROWTH
13.6 OTHER INDICATIONS
14 NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 FDA approvals, expanding clinical pipelines, and strategic collaborations drive market
14.2.2 CANADA
14.2.2.1 Increasing access to innovative NDC therapies drives growth
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Access to innovative therapies and strong radioligand infrastructure are driving growth
14.3.2 UK
14.3.2.1 Rising demand for precision oncology and advanced conjugate technologies drives market expansion
14.3.3 FRANCE
14.3.3.1 Biopharma presence and global innovation in targeted conjugates support market growth
14.3.4 ITALY
14.3.4.1 Expanding clinical research to accelerate market growth
14.3.5 SPAIN
14.3.5.1 Increased focus on research for NDC development to propel market growth
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 Strong domestic innovation and expanding oncology demand drive NDC market growth
14.4.2 JAPAN
14.4.2.1 Growing drug approvals and pharma biotech research initiatives support market growth
14.4.3 INDIA
14.4.3.1 Expanding biologics capabilities and rising demand for targeted oncology therapies support growth
14.4.4 SOUTH KOREA
14.4.4.1 Key drug approvals relevant to NDC market to aid growth in South Korea
14.4.5 AUSTRALIA
14.4.5.1 Strong regulatory framework, clinical innovation, and global partnerships drive market growth
14.4.6 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 BRAZIL
14.5.1.1 Expanding clinical trials and rising demand for targeted oncology therapies drive market growth
14.5.2 MEXICO
14.5.2.1 Gradual increase in pharmaceutical R&D to support market growth
14.5.3 REST OF LATIN AMERICA
14.6 MIDDLE EAST
14.6.1 GCC COUNTRIES
14.6.1.1 Integration of genomics, biomarker-driven diagnostics, and personalized treatment to propel market
14.6.2 REST OF MIDDLE EAST
14.7 AFRICA
14.7.1 RESEARCH COLLABORATIONS AND INFRASTRUCTURAL DEVELOPMENT TO DRIVE MARKET
15 COMPETITIVE LANDSCAPE
15.1 OVERVIEW
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.3 REVENUE ANALYSIS, 2021–2025
15.4 MARKET SHARE ANALYSIS
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Type footprint
15.5.5.4 Indication footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
15.6.5.1 Detailed list of key startups/SMEs
15.7 COMPANY VALUATION AND FINANCIAL METRICS
15.8 BRAND COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 ASTRAZENECA
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product approvals
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 MnM view
16.1.1.4.1 Key strengths/Right to win
16.1.1.4.2 Strategic choices made
16.1.1.4.3 Weaknesses and competitive threats
16.1.2 DAIICHI SANKYO COMPANY, LIMITED
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Products in pipeline
16.1.2.4 Recent developments
16.1.2.4.1 Product approvals
16.1.2.4.2 Expansions
16.1.2.5 MnM view
16.1.2.5.1 Key strengths/Right to win
16.1.2.5.2 Strategic choices made
16.1.2.5.3 Weaknesses and competitive threats
16.1.3 NOVARTIS AG
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product approvals
16.1.3.3.2 Deals
16.1.3.3.3 Expansions
16.1.3.4 MnM view
16.1.3.4.1 Key strengths/Right to win
16.1.3.4.2 Strategic choices made
16.1.3.4.3 Weaknesses and competitive threats
16.1.4 ALNYLAM PHARMACEUTICALS, INC
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product approvals
16.1.4.3.2 Deals
16.1.4.3.3 Expansions
16.1.4.4 MnM view
16.1.4.4.1 Key strengths/Right to win
16.1.4.4.2 Strategic choices made
16.1.4.4.3 Weaknesses and competitive threats
16.1.5 GILEAD SCIENCES, INC.
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Deals
16.1.5.3.2 Expansions
16.1.5.4 MnM view
16.1.5.4.1 Key strengths/Right to win
16.1.5.4.2 Strategic choices made
16.1.5.4.3 Weaknesses and competitive threats
16.1.6 IONIS PHARMACEUTICALS, INC.
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Products in pipeline
16.1.6.4 Recent developments
16.1.6.4.1 Product approvals
16.1.6.4.2 Deals
16.1.7 RAKUTEN GROUP, INC.
16.1.7.1 Business overview
16.1.7.2 Products in pipeline
16.1.7.3 Recent developments
16.1.7.3.1 Deals
16.1.8 NOVO NORDISK
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Product approvals
16.1.8.3.2 Deals
16.1.9 ADC THERAPEUTICS SA
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Products in pipeline
16.1.10 SANOFI
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Products in pipeline
16.1.10.4 Recent developments
16.1.10.4.1 Deals
16.1.11 ARROWHEAD PHARMACEUTICALS
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product approvals
16.1.12 ABBVIE INC.
16.1.12.1 Business overview
16.1.12.2 Products in pipeline
16.1.13 REGENERON PHARMACEUTICALS INC.
16.1.13.1 Business overview
16.1.13.2 Products in pipeline
16.2 OTHER PLAYERS
16.2.1 BICYCLE THERAPEUTICS
16.2.2 AVIDITY BIOSCIENCES
16.2.3 SILENCE THERAPEUTICS
16.2.4 MEDILINK THERAPEUTICS
16.2.5 SYSTIMMUNE, INC.
16.2.6 ACTINIUM PHARMACEUTICALS
16.2.7 ALPHAMAB ONCOLOGY
16.2.8 FUSION PHARMA
16.2.9 ORANO GROUP
16.2.10 PEPGEN INC
16.2.11 TUBULIS GMBH
16.2.12 CLARITY PHARMACEUTICALS
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY DATA
17.1.2 PRIMARY DATA
17.2 MARKET ESTIMATION METHODOLOGY
17.2.1 MARKET SIZE ESTIMATION
17.2.2 INSIGHTS OF PRIMARY EXPERTS
17.2.3 TOP-DOWN APPROACH
17.3 MARKET GROWTH RATE PROJECTIONS
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
17.5 RESEARCH ASSUMPTIONS
17.6 RESEARCH LIMITATIONS
17.7 RISK ANALYSIS
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED AND REGIONS CONSIDERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 NEXT-GENERATION DRUG CONJUGATES MARKET OVERVIEW
3.2 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND & REGION
3.3 NEXT-GENERATION DRUG CONJUGATES MARKET: GEOGRAPHIC SNAPSHOT
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Increasing clinical success and regulatory approvals of antibody-drug conjugates
4.2.1.2 Technological advancements in linker chemistry and payload development
4.2.2 RESTRAINTS
4.2.2.1 High development and manufacturing costs associated with complex biologics
4.2.3 OPPORTUNITIES
4.2.3.1 Expansion of drug conjugates into non-oncology therapeutic areas
4.2.3.2 Increasing developments of novel conjugate platforms
4.2.4 CHALLENGES
4.2.4.1 Concerns related to biocompatibility, safety, and adverse immune responses
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
4.4.2 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE
4.4.3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE
4.4.4 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE SELLING PRICE, BY KEY PLAYER, 2025 (USD)
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
5.5.3 AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD)
5.6 KEY CONFERENCES & EVENTS
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.8 INVESTMENT & FUNDING ACTIVITY
5.9 IMPACT OF US TARIFFS—NEXT-GENERATION DRUG CONJUGATES MARKET
5.9.1 INTRODUCTION
5.9.2 KEY TARIFF RATES
5.9.3 PRICE IMPACT ANALYSIS
5.9.4 IMPACT ON COUNTRIES/REGIONS
5.9.4.1 North America
5.9.4.2 Europe
5.9.4.3 Asia Pacific
5.9.5 IMPACT ON END-USE INDUSTRIES
5.9.5.1 Hospitals
5.9.5.2 Specialty clinics and cancer centers
5.9.5.3 Other specialty care settings
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY TECHNOLOGIES
6.1.1.1 New-generation payload chemistries
6.1.1.2 Radioligand/theranostic conjugate engineering
6.1.2 ADJACENT TECHNOLOGIES
6.1.2.1 Protein engineering/antibody engineering
6.1.3 COMPLEMENTARY TECHNOLOGIES
6.1.3.1 Diagnostic imaging/theranostics workflows
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 FUTURE APPLICATIONS
6.4 IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET
6.4.1 TOP USE CASES AND MARKET POTENTIAL
6.4.2 CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION DRUG CONJUGATES MARKET
6.4.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.4.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN NEXT-GENERATION DRUG CONJUGATES MARKET
6.5 PIPELINE ANALYSIS
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT
7.1.2.1 Reimbursement scenario
7.1.3 INDUSTRY STANDARDS
7.1.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM END USERS
8.5 MARKET PROFITABILITY
9 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 ENHERTU
9.2.1 BROAD CLINICAL ADOPTION AND REGULATORY EXPANSION OF TARGETED ADC THERAPIES DRIVE MARKET GROWTH
9.3 PLUVICTO
9.3.1 EXPANDING USE OF TARGETED RADIOLIGAND THERAPY IN PROSTATE CANCER TO DRIVE MARKET GROWTH
9.4 AMVUTTRA
9.4.1 ADVANCING RNAI THERAPEUTICS THROUGH DURABLE GENE SILENCING AND EXPANDED INDICATION REACH
9.5 TRODELVY
9.5.1 RISING GOVERNMENT APPROVALS FOR BREAST CANCER TREATMENTS TO DRIVE MARKET GROWTH
9.6 SACITUZUMAB TIRUMOTECAN
9.6.1 ADVANCING NEXT-GENERATION ADC PAYLOAD INNOVATION IN NDC MARKET
9.7 PATRITUMAB DERUXTECAN
9.7.1 ADVANCEMENTS IN HER3-DIRECTED ANTIBODY-DRUG CONJUGATES TO AID GROWTH
9.8 225AC-PSMA-617
9.8.1 POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO SUPPORT MARKET GROWTH
9.9 OTHER COMMERCIALIZED PRODUCTS
9.10 OTHER PIPELINE PRODUCTS
10 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE
10.1 INTRODUCTION
10.2 ANTIBODY–SMALL MOLECULE CONJUGATES
10.2.1 ENHANCED CLINICAL UTILITY AND TECHNOLOGICAL INNOVATION TO DRIVE MARKET
10.3 PEPTIDE–RADIONUCLIDE CONJUGATES
10.3.1 INNOVATIONS IN PRECISION ONCOLOGY APPLICATIONS AND TECHNOLOGICAL ADVANCEMENTS SUPPORT GROWTH
10.4 LIGAND–OLIGONUCLEOTIDE CONJUGATES
10.4.1 ENHANCED DELIVERY AND TISSUE TARGETING CAPABILITIES OF LIGAND–OLIGONUCLEOTIDE CONJUGATES DRIVE GROWTH
10.5 OTHER DRUG CONJUGATES
11 NEXT-GENERATION DRUG MARKET, BY TARGET LIGAND
11.1 INTRODUCTION
11.2 ANTIBODIES
11.2.1 ADVANCEMENTS IN ANTIBODY ENGINEERING AND EXPANDING TARGET DIVERSITY DRIVE GROWTH
11.3 AMINO SUGARS
11.3.1 GROWING ADOPTION OF GALNAC-BASED LIVER-TARGETING PLATFORMS DRIVES EXPANSION
11.4 SMALL MOLECULES
11.4.1 EXPANDING USE OF SMALL-MOLECULE TARGETING LIGANDS IS BROADENING THE NEXT-GENERATION DRUG CONJUGATES MARKET
11.5 PEPTIDES
11.5.1 EXPANDING CLINICAL PIPELINES AND TUMOR-TARGETING INNOVATIONS PROPEL GROWTH
12 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE
12.1 INTRODUCTION
12.2 SMALL-MOLECULE PAYLOADS
12.2.1 RISING ADOPTION OF HIGHLY POTENT, NEXT-GENERATION PAYLOADS AND ADVANCED LINKER TECHNOLOGIES IS ACCELERATING GROWTH
12.3 OLIGONUCLEOTIDE PAYLOADS
12.3.1 RISING ADOPTION OF RNA-BASED GENE-SILENCING THERAPIES AND LONG-ACTING CONJUGATE PLATFORMS TO DRIVE MARKET
12.4 RADIONUCLIDE PAYLOADS
12.4.1 EXPANDING RADIOLIGAND THERAPY ADOPTION AND ADVANCEMENTS IN ISOTOPE TECHNOLOGIES SUPPORT MARKET GROWTH
13 NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION
13.1 INTRODUCTION
13.2 BREAST CANCER
13.2.1 RISING INCIDENCE AND INCREASING ADOPTION OF TARGETED ADC THERAPIES TO DRIVE MARKET
13.3 HATTR WITH POLYNEUROPATHY
13.3.1 ADVANCEMENTS IN RNA-BASED GENE-SILENCING THERAPIES AND INCREASING DIAGNOSIS RATES ARE DRIVING GROWTH
13.4 PROSTATE CANCER
13.4.1 EXPANDING ADOPTION OF PSMA-TARGETED RADIOLIGAND THERAPIES IS DRIVING GROWTH
13.5 PRIMARY HYPERLIPIDEMIA
13.5.1 INCREASING ADOPTION OF LONG-ACTING RNA-BASED THERAPIES DRIVES MARKET GROWTH
13.6 OTHER INDICATIONS
14 NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 FDA approvals, expanding clinical pipelines, and strategic collaborations drive market
14.2.2 CANADA
14.2.2.1 Increasing access to innovative NDC therapies drives growth
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Access to innovative therapies and strong radioligand infrastructure are driving growth
14.3.2 UK
14.3.2.1 Rising demand for precision oncology and advanced conjugate technologies drives market expansion
14.3.3 FRANCE
14.3.3.1 Biopharma presence and global innovation in targeted conjugates support market growth
14.3.4 ITALY
14.3.4.1 Expanding clinical research to accelerate market growth
14.3.5 SPAIN
14.3.5.1 Increased focus on research for NDC development to propel market growth
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 Strong domestic innovation and expanding oncology demand drive NDC market growth
14.4.2 JAPAN
14.4.2.1 Growing drug approvals and pharma biotech research initiatives support market growth
14.4.3 INDIA
14.4.3.1 Expanding biologics capabilities and rising demand for targeted oncology therapies support growth
14.4.4 SOUTH KOREA
14.4.4.1 Key drug approvals relevant to NDC market to aid growth in South Korea
14.4.5 AUSTRALIA
14.4.5.1 Strong regulatory framework, clinical innovation, and global partnerships drive market growth
14.4.6 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 BRAZIL
14.5.1.1 Expanding clinical trials and rising demand for targeted oncology therapies drive market growth
14.5.2 MEXICO
14.5.2.1 Gradual increase in pharmaceutical R&D to support market growth
14.5.3 REST OF LATIN AMERICA
14.6 MIDDLE EAST
14.6.1 GCC COUNTRIES
14.6.1.1 Integration of genomics, biomarker-driven diagnostics, and personalized treatment to propel market
14.6.2 REST OF MIDDLE EAST
14.7 AFRICA
14.7.1 RESEARCH COLLABORATIONS AND INFRASTRUCTURAL DEVELOPMENT TO DRIVE MARKET
15 COMPETITIVE LANDSCAPE
15.1 OVERVIEW
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.3 REVENUE ANALYSIS, 2021–2025
15.4 MARKET SHARE ANALYSIS
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Type footprint
15.5.5.4 Indication footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
15.6.5.1 Detailed list of key startups/SMEs
15.7 COMPANY VALUATION AND FINANCIAL METRICS
15.8 BRAND COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 ASTRAZENECA
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product approvals
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 MnM view
16.1.1.4.1 Key strengths/Right to win
16.1.1.4.2 Strategic choices made
16.1.1.4.3 Weaknesses and competitive threats
16.1.2 DAIICHI SANKYO COMPANY, LIMITED
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Products in pipeline
16.1.2.4 Recent developments
16.1.2.4.1 Product approvals
16.1.2.4.2 Expansions
16.1.2.5 MnM view
16.1.2.5.1 Key strengths/Right to win
16.1.2.5.2 Strategic choices made
16.1.2.5.3 Weaknesses and competitive threats
16.1.3 NOVARTIS AG
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product approvals
16.1.3.3.2 Deals
16.1.3.3.3 Expansions
16.1.3.4 MnM view
16.1.3.4.1 Key strengths/Right to win
16.1.3.4.2 Strategic choices made
16.1.3.4.3 Weaknesses and competitive threats
16.1.4 ALNYLAM PHARMACEUTICALS, INC
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product approvals
16.1.4.3.2 Deals
16.1.4.3.3 Expansions
16.1.4.4 MnM view
16.1.4.4.1 Key strengths/Right to win
16.1.4.4.2 Strategic choices made
16.1.4.4.3 Weaknesses and competitive threats
16.1.5 GILEAD SCIENCES, INC.
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Deals
16.1.5.3.2 Expansions
16.1.5.4 MnM view
16.1.5.4.1 Key strengths/Right to win
16.1.5.4.2 Strategic choices made
16.1.5.4.3 Weaknesses and competitive threats
16.1.6 IONIS PHARMACEUTICALS, INC.
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Products in pipeline
16.1.6.4 Recent developments
16.1.6.4.1 Product approvals
16.1.6.4.2 Deals
16.1.7 RAKUTEN GROUP, INC.
16.1.7.1 Business overview
16.1.7.2 Products in pipeline
16.1.7.3 Recent developments
16.1.7.3.1 Deals
16.1.8 NOVO NORDISK
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Product approvals
16.1.8.3.2 Deals
16.1.9 ADC THERAPEUTICS SA
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Products in pipeline
16.1.10 SANOFI
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Products in pipeline
16.1.10.4 Recent developments
16.1.10.4.1 Deals
16.1.11 ARROWHEAD PHARMACEUTICALS
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product approvals
16.1.12 ABBVIE INC.
16.1.12.1 Business overview
16.1.12.2 Products in pipeline
16.1.13 REGENERON PHARMACEUTICALS INC.
16.1.13.1 Business overview
16.1.13.2 Products in pipeline
16.2 OTHER PLAYERS
16.2.1 BICYCLE THERAPEUTICS
16.2.2 AVIDITY BIOSCIENCES
16.2.3 SILENCE THERAPEUTICS
16.2.4 MEDILINK THERAPEUTICS
16.2.5 SYSTIMMUNE, INC.
16.2.6 ACTINIUM PHARMACEUTICALS
16.2.7 ALPHAMAB ONCOLOGY
16.2.8 FUSION PHARMA
16.2.9 ORANO GROUP
16.2.10 PEPGEN INC
16.2.11 TUBULIS GMBH
16.2.12 CLARITY PHARMACEUTICALS
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY DATA
17.1.2 PRIMARY DATA
17.2 MARKET ESTIMATION METHODOLOGY
17.2.1 MARKET SIZE ESTIMATION
17.2.2 INSIGHTS OF PRIMARY EXPERTS
17.2.3 TOP-DOWN APPROACH
17.3 MARKET GROWTH RATE PROJECTIONS
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
17.5 RESEARCH ASSUMPTIONS
17.6 RESEARCH LIMITATIONS
17.7 RISK ANALYSIS
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 NEXT-GENERATION DRUG CONJUGATES MARKET: IMPACT ANALYSIS
TABLE 2 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
TABLE 3 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 5 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE, 2022–2029 (USD MILLION)
TABLE 6 NEXT-GENERATION DRUG CONJUGATES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7 NEXT-GENERATION DRUG CONJUGATES MARKET: ROLE IN ECOSYSTEM
TABLE 8 INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD)
TABLE 9 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
TABLE 10 AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD)
TABLE 11 NEXT-GENERATION DRUG CONJUGATES MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 13 CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION DRUG CONJUGATES MARKET
TABLE 14 CLIENT’S READINESS TO ADOPT GENERATIVE AI
TABLE 15 KEY PIPELINE PRODUCTS IN NEXT-GENERATION DRUG CONJUGATES MARKET
(AS OF MARCH 2026)
TABLE 16 EXAMPLES OF US REGULATORY PATHWAY, BY TYPE OF DRUG CONJUGATE
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 REIMBURSEMENT STATUS AND TYPE, BY COUNTRY
TABLE 22 COUNTRY-WISE REGULATORY SCENARIO FOR NEXT-GENERATION DRUG CONJUGATE MANUFACTURERS
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)
TABLE 24 KEY BUYING CRITERIA, BY END USER
TABLE 25 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 26 NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2024–2035 (USD MILLION)
TABLE 27 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 28 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 29 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 30 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 31 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2024–2035 (USD MILLION)
TABLE 32 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY REGION, 2024–2035 (USD MILLION)
TABLE 33 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 34 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 35 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 36 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO , BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 37 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY REGION, 2024–2035 (USD MILLION)
TABLE 38 NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024–2035 (USD MILLION)
TABLE 39 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 40 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 41 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 42 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 43 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024–2035 (USD MILLION)
TABLE 44 NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024–2035 (USD MILLION)
TABLE 45 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 46 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 47 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 48 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 49 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024–2035 (USD MILLION)
TABLE 50 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024–2035 (USD MILLION)
TABLE 51 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 52 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 53 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 54 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 55 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024–2035 (USD MILLION)
TABLE 56 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024–2035 (USD MILLION)
TABLE 57 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 58 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 59 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 60 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 61 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024–2035 (USD MILLION)
TABLE 62 NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY REGION, 2024–2035 (USD MILLION)
TABLE 63 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 64 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 65 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 66 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 67 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY REGION, 2024–2035 (USD MILLION)
TABLE 68 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024–2035 (USD MILLION)
TABLE 69 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 70 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 71 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 72 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 73 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024–2035 (USD MILLION)
TABLE 74 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY REGION, 2024–2035 (USD MILLION)
TABLE 75 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 76 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 77 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 78 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 79 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY REGION, 2024–2035 (USD MILLION)
TABLE 80 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 81 ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 82 NORTH AMERICA: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 83 EUROPE: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 84 ASIA PACIFIC: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 85 LATIN AMERICA: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 86 MIDDLE EAST: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 87 PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 88 NORTH AMERICA: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 89 EUROPE: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 90 ASIA PACIFIC: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 91 LATIN AMERICA: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 92 MIDDLE EAST: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 93 LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 94 NORTH AMERICA: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 95 EUROPE: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 96 ASIA PACIFIC: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 97 LATIN AMERICA: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 98 MIDDLE EAST: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 99 OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 100 NORTH AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 101 EUROPE: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 102 ASIA PACIFIC: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 103 LATIN AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 104 MIDDLE EAST: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 105 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 106 NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY REGION, 2024–2035 (USD MILLION)
TABLE 107 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 108 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 109 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 110 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 111 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY REGION, 2024–2035 (USD MILLION)
TABLE 112 NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY REGION, 2024–2035 (USD MILLION)
TABLE 113 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 114 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 115 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 116 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 117 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY REGION, 2024–2035 (USD MILLION)
TABLE 118 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2035 (USD MILLION)
TABLE 119 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 120 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 121 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 122 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 123 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2035 (USD MILLION)
TABLE 124 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY REGION, 2024–2035 (USD MILLION)
TABLE 125 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 126 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 127 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 128 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 129 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY REGION, 2024–2035 (USD MILLION)
TABLE 130 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 131 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 132 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 133 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 134 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 135 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 136 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 137 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 138 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 139 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 140 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 141 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 142 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 143 NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 144 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 145 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 146 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 147 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 148 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 149 NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 150 NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2024–2035 (USD MILLION)
TABLE 151 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 152 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 153 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 154 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 155 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2024–2035 (USD MILLION)
TABLE 156 NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY REGION, 2024–2035 (USD MILLION)
TABLE 157 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 158 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 159 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 160 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 161 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY REGION, 2024–2035 (USD MILLION)
TABLE 162 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2035 (USD MILLION)
TABLE 163 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 164 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 165 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 166 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 167 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2035 (USD MILLION)
TABLE 168 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY REGION, 2024–2035 (USD MILLION)
TABLE 169 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 170 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 171 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 172 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 173 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY REGION, 2024–2035 (USD MILLION)
TABLE 174 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2035 (USD MILLION)
TABLE 175 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 176 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 177 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 178 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 179 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2035 (USD MILLION)
TABLE 180 NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 181 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 182 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 183 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 184 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 185 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 186 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 187 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 188 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 189 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 190 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 191 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 192 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 193 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 194 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 195 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 196 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 197 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 198 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 199 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 200 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 201 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 202 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 203 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 204 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 205 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 206 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 207 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 208 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 209 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 210 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 211 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 212 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 1 NEXT-GENERATION DRUG CONJUGATES MARKET: IMPACT ANALYSIS
TABLE 2 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
TABLE 3 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 5 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE, 2022–2029 (USD MILLION)
TABLE 6 NEXT-GENERATION DRUG CONJUGATES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7 NEXT-GENERATION DRUG CONJUGATES MARKET: ROLE IN ECOSYSTEM
TABLE 8 INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD)
TABLE 9 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
TABLE 10 AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD)
TABLE 11 NEXT-GENERATION DRUG CONJUGATES MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 13 CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION DRUG CONJUGATES MARKET
TABLE 14 CLIENT’S READINESS TO ADOPT GENERATIVE AI
TABLE 15 KEY PIPELINE PRODUCTS IN NEXT-GENERATION DRUG CONJUGATES MARKET
(AS OF MARCH 2026)
TABLE 16 EXAMPLES OF US REGULATORY PATHWAY, BY TYPE OF DRUG CONJUGATE
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 REIMBURSEMENT STATUS AND TYPE, BY COUNTRY
TABLE 22 COUNTRY-WISE REGULATORY SCENARIO FOR NEXT-GENERATION DRUG CONJUGATE MANUFACTURERS
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)
TABLE 24 KEY BUYING CRITERIA, BY END USER
TABLE 25 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 26 NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2024–2035 (USD MILLION)
TABLE 27 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 28 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 29 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 30 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 31 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2024–2035 (USD MILLION)
TABLE 32 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY REGION, 2024–2035 (USD MILLION)
TABLE 33 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 34 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 35 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 36 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO , BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 37 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY REGION, 2024–2035 (USD MILLION)
TABLE 38 NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024–2035 (USD MILLION)
TABLE 39 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 40 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 41 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 42 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 43 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024–2035 (USD MILLION)
TABLE 44 NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024–2035 (USD MILLION)
TABLE 45 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 46 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 47 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 48 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 49 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024–2035 (USD MILLION)
TABLE 50 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024–2035 (USD MILLION)
TABLE 51 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 52 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 53 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 54 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 55 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024–2035 (USD MILLION)
TABLE 56 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024–2035 (USD MILLION)
TABLE 57 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 58 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 59 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 60 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 61 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024–2035 (USD MILLION)
TABLE 62 NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY REGION, 2024–2035 (USD MILLION)
TABLE 63 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 64 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 65 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 66 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 67 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY REGION, 2024–2035 (USD MILLION)
TABLE 68 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024–2035 (USD MILLION)
TABLE 69 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 70 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 71 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 72 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 73 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024–2035 (USD MILLION)
TABLE 74 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY REGION, 2024–2035 (USD MILLION)
TABLE 75 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 76 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 77 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 78 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 79 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY REGION, 2024–2035 (USD MILLION)
TABLE 80 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 81 ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 82 NORTH AMERICA: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 83 EUROPE: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 84 ASIA PACIFIC: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 85 LATIN AMERICA: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 86 MIDDLE EAST: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 87 PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 88 NORTH AMERICA: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 89 EUROPE: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 90 ASIA PACIFIC: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 91 LATIN AMERICA: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 92 MIDDLE EAST: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 93 LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 94 NORTH AMERICA: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 95 EUROPE: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 96 ASIA PACIFIC: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 97 LATIN AMERICA: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 98 MIDDLE EAST: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 99 OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 100 NORTH AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 101 EUROPE: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 102 ASIA PACIFIC: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 103 LATIN AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 104 MIDDLE EAST: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 105 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 106 NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY REGION, 2024–2035 (USD MILLION)
TABLE 107 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 108 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 109 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 110 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 111 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY REGION, 2024–2035 (USD MILLION)
TABLE 112 NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY REGION, 2024–2035 (USD MILLION)
TABLE 113 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 114 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 115 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 116 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 117 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY REGION, 2024–2035 (USD MILLION)
TABLE 118 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2035 (USD MILLION)
TABLE 119 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 120 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 121 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 122 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 123 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2035 (USD MILLION)
TABLE 124 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY REGION, 2024–2035 (USD MILLION)
TABLE 125 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 126 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 127 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 128 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 129 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY REGION, 2024–2035 (USD MILLION)
TABLE 130 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 131 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 132 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 133 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 134 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 135 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 136 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 137 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 138 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 139 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 140 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 141 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 142 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 143 NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 144 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 145 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 146 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 147 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 148 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)
TABLE 149 NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 150 NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2024–2035 (USD MILLION)
TABLE 151 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 152 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 153 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 154 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 155 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2024–2035 (USD MILLION)
TABLE 156 NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY REGION, 2024–2035 (USD MILLION)
TABLE 157 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 158 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 159 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 160 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 161 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY REGION, 2024–2035 (USD MILLION)
TABLE 162 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2035 (USD MILLION)
TABLE 163 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 164 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 165 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 166 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 167 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2035 (USD MILLION)
TABLE 168 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY REGION, 2024–2035 (USD MILLION)
TABLE 169 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 170 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 171 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 172 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 173 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY REGION, 2024–2035 (USD MILLION)
TABLE 174 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2035 (USD MILLION)
TABLE 175 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 176 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 177 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 178 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 179 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2035 (USD MILLION)
TABLE 180 NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)
TABLE 181 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 182 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 183 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 184 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 185 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 186 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 187 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 188 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 189 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 190 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 191 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 192 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 193 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 194 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 195 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 196 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 197 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)
TABLE 198 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 199 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 200 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 201 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 202 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 203 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 204 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 205 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 206 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 207 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
TABLE 208 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)
TABLE 209 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)
TABLE 210 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)
TABLE 211 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)
TABLE 212 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)
LIST OF FIGURES
FIGURE 1 MARKET SCENARIO
FIGURE 2 GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET, 2024–2035
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY MARKET PLAYERS, 2023–2026
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF NEXT-GENERATION DRUG CONJUGATES MARKET
FIGURE 5 HIGH-GROWTH SEGMENTS IN NEXT-GENERATION DRUG CONJUGATES MARKET, 2026–2035
FIGURE 6 NORTH AMERICA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 7 TECHNOLOGICAL ADVANCEMENTS IN LINKER CHEMISTRY AND PAYLOAD DEVELOPMENT TO DRIVE GROWTH
FIGURE 8 ANTIBODY SEGMENT IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025
FIGURE 9 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 10 NEXT-GENERATION DRUG CONJUGATES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11 NEXT-GENERATION DRUG CONJUGATES MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 12 NEXT-GENERATION DRUG CONJUGATES MARKET: VALUE CHAIN ANALYSIS
FIGURE 13 NEXT-GENERATION DRUG CONJUGATES MARKET: ECOSYSTEM ANALYSIS
FIGURE 14 INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD)
FIGURE 15 INDICATIVE SELLING PRICE, BY REGION, 2025 (USD)
FIGURE 16 NEXT-GENERATION DRUG CONJUGATES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 17 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
FIGURE 18 IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE
FIGURE 20 KEY BUYING CRITERIA, BY END USER
FIGURE 21 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT
FIGURE 22 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT
FIGURE 23 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)
FIGURE 24 MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 25 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 26 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY FOOTPRINT
FIGURE 27 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 28 EV/EBITDA OF KEY VENDORS
FIGURE 29 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 30 NEXT-GENERATION DRUG CONJUGATES MARKET: BRAND COMPARATIVE ANALYSIS
FIGURE 31 ASTRAZENECA: COMPANY SNAPSHOT (2025)
FIGURE 32 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2024)
FIGURE 33 NOVARTIS AG: COMPANY SNAPSHOT (2025)
FIGURE 34 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025)
FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 36 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024)
FIGURE 37 RAKUTEN GROUP, INC.: COMPANY SNAPSHOT (2025)
FIGURE 38 NOVO NORDISK: COMPANY SNAPSHOT (2025)
FIGURE 39 ADC THERAPEUTICS SA: COMPANY SNAPSHOT (2025)
FIGURE 40 SANOFI: COMPANY SNAPSHOT (2025)
FIGURE 41 ARROWHEAD PHARMACEUTICALS: COMPANY SNAPSHOT (2025)
FIGURE 42 RESEARCH DESIGN
FIGURE 43 NEXT-GENERATION DRUG CONJUGATES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 44 NEXT-GENERATION DRUG CONJUGATES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 45 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
FIGURE 46 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF ALNYLAM PHARMACEUTICALS (2025)
FIGURE 47 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 48 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 49 NEXT-GENERATION DRUG CONJUGATES MARKET CAGR PROJECTIONS
FIGURE 50 DATA TRIANGULATION METHODOLOGY
FIGURE 1 MARKET SCENARIO
FIGURE 2 GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET, 2024–2035
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY MARKET PLAYERS, 2023–2026
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF NEXT-GENERATION DRUG CONJUGATES MARKET
FIGURE 5 HIGH-GROWTH SEGMENTS IN NEXT-GENERATION DRUG CONJUGATES MARKET, 2026–2035
FIGURE 6 NORTH AMERICA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 7 TECHNOLOGICAL ADVANCEMENTS IN LINKER CHEMISTRY AND PAYLOAD DEVELOPMENT TO DRIVE GROWTH
FIGURE 8 ANTIBODY SEGMENT IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025
FIGURE 9 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 10 NEXT-GENERATION DRUG CONJUGATES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11 NEXT-GENERATION DRUG CONJUGATES MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 12 NEXT-GENERATION DRUG CONJUGATES MARKET: VALUE CHAIN ANALYSIS
FIGURE 13 NEXT-GENERATION DRUG CONJUGATES MARKET: ECOSYSTEM ANALYSIS
FIGURE 14 INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD)
FIGURE 15 INDICATIVE SELLING PRICE, BY REGION, 2025 (USD)
FIGURE 16 NEXT-GENERATION DRUG CONJUGATES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 17 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
FIGURE 18 IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE
FIGURE 20 KEY BUYING CRITERIA, BY END USER
FIGURE 21 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT
FIGURE 22 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT
FIGURE 23 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)
FIGURE 24 MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 25 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 26 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY FOOTPRINT
FIGURE 27 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 28 EV/EBITDA OF KEY VENDORS
FIGURE 29 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 30 NEXT-GENERATION DRUG CONJUGATES MARKET: BRAND COMPARATIVE ANALYSIS
FIGURE 31 ASTRAZENECA: COMPANY SNAPSHOT (2025)
FIGURE 32 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2024)
FIGURE 33 NOVARTIS AG: COMPANY SNAPSHOT (2025)
FIGURE 34 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025)
FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 36 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024)
FIGURE 37 RAKUTEN GROUP, INC.: COMPANY SNAPSHOT (2025)
FIGURE 38 NOVO NORDISK: COMPANY SNAPSHOT (2025)
FIGURE 39 ADC THERAPEUTICS SA: COMPANY SNAPSHOT (2025)
FIGURE 40 SANOFI: COMPANY SNAPSHOT (2025)
FIGURE 41 ARROWHEAD PHARMACEUTICALS: COMPANY SNAPSHOT (2025)
FIGURE 42 RESEARCH DESIGN
FIGURE 43 NEXT-GENERATION DRUG CONJUGATES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 44 NEXT-GENERATION DRUG CONJUGATES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 45 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
FIGURE 46 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF ALNYLAM PHARMACEUTICALS (2025)
FIGURE 47 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 48 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 49 NEXT-GENERATION DRUG CONJUGATES MARKET CAGR PROJECTIONS
FIGURE 50 DATA TRIANGULATION METHODOLOGY
